Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease

Laura Sonzogni, Laura Silvestri, Annalisa De Silvestri, Chiara Gritti, Luciana Foti, Claudio Zavaglia, Riccardo Bottelli, Mario U. Mondelli, Emilio Civardi, Enrico M. Silini

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Factors influencing the progression of liver disease and the development of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV) infection are poorly understood. Inherited variations of drug-metabolizing enzyme (DME) activities may affect liver damage and cancer risk by modifying individual susceptibility to endogenous or exogenous toxic compounds. We investigated the association of liver disease severity with common alleles of microsomal epoxide hydrolase (mEH), an enzyme involved in the metabolism of highly reactive epoxide intermediates. Three polymorphisms (Tyr113His, His139Arg, and -613C/T) were analyzed by polymerase chain reaction (PCR) restriction fragment length polymorphisms (RFLPs) in 394 patients at different stages of disease, including 92 asymptomatic carriers, 109 patients with chronic hepatitis, 100 patients with cirrhosis, and 93 patients with HCC. Reference allele frequencies were obtained from 99 healthy blood donors. Allele distributions between categories were compared using the χ2 test; odds ratios (ORs) and 95% CI were calculated to express relative risks. Allele frequencies among 99 healthy controls were as follows: 15.1% for 113His/His, 4.0% for 139Arg/Arg, and 46.5% for -613C/T. mEH 113His/His homozygotes were overrepresented in advanced stages of disease, in particular among HCC patients (27.9%; P = .03; OR, 2.2; 95% CI, 1.0-4.6). Differences were more pronounced among men and between extreme patient categories. When mEH genotypes were combined to express a metabolic phenotype, very slow metabolizers were highly prevalent among cirrhotic and HCC patients (18% vs. 3.3% in carriers; P <.001). In conclusion, mEH gene polymorphisms were significantly associated with HCV-related liver disease severity and HCC risk. Men were at higher risk than women; this might be explained by hormonal regulation of gene expression or by differential exposure to environmental toxins.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalHepatology
Volume36
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Epoxide Hydrolases
Hepacivirus
Liver Diseases
Hepatocellular Carcinoma
Genes
Gene Frequency
Alleles
Odds Ratio
Poisons
Epoxy Compounds
Environmental Exposure
Homozygote
Gene Expression Regulation
Chronic Hepatitis C
Virus Diseases
Enzymes
Chronic Hepatitis
Liver Neoplasms
Blood Donors
Restriction Fragment Length Polymorphisms

ASJC Scopus subject areas

  • Hepatology

Cite this

Sonzogni, L., Silvestri, L., De Silvestri, A., Gritti, C., Foti, L., Zavaglia, C., ... Silini, E. M. (2002). Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology, 36(1), 195-201. https://doi.org/10.1053/jhep.2002.33898

Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. / Sonzogni, Laura; Silvestri, Laura; De Silvestri, Annalisa; Gritti, Chiara; Foti, Luciana; Zavaglia, Claudio; Bottelli, Riccardo; Mondelli, Mario U.; Civardi, Emilio; Silini, Enrico M.

In: Hepatology, Vol. 36, No. 1, 2002, p. 195-201.

Research output: Contribution to journalArticle

Sonzogni, L, Silvestri, L, De Silvestri, A, Gritti, C, Foti, L, Zavaglia, C, Bottelli, R, Mondelli, MU, Civardi, E & Silini, EM 2002, 'Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease', Hepatology, vol. 36, no. 1, pp. 195-201. https://doi.org/10.1053/jhep.2002.33898
Sonzogni, Laura ; Silvestri, Laura ; De Silvestri, Annalisa ; Gritti, Chiara ; Foti, Luciana ; Zavaglia, Claudio ; Bottelli, Riccardo ; Mondelli, Mario U. ; Civardi, Emilio ; Silini, Enrico M. / Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. In: Hepatology. 2002 ; Vol. 36, No. 1. pp. 195-201.
@article{4bd0d31375b4484880ab2adf55762804,
title = "Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease",
abstract = "Factors influencing the progression of liver disease and the development of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV) infection are poorly understood. Inherited variations of drug-metabolizing enzyme (DME) activities may affect liver damage and cancer risk by modifying individual susceptibility to endogenous or exogenous toxic compounds. We investigated the association of liver disease severity with common alleles of microsomal epoxide hydrolase (mEH), an enzyme involved in the metabolism of highly reactive epoxide intermediates. Three polymorphisms (Tyr113His, His139Arg, and -613C/T) were analyzed by polymerase chain reaction (PCR) restriction fragment length polymorphisms (RFLPs) in 394 patients at different stages of disease, including 92 asymptomatic carriers, 109 patients with chronic hepatitis, 100 patients with cirrhosis, and 93 patients with HCC. Reference allele frequencies were obtained from 99 healthy blood donors. Allele distributions between categories were compared using the χ2 test; odds ratios (ORs) and 95{\%} CI were calculated to express relative risks. Allele frequencies among 99 healthy controls were as follows: 15.1{\%} for 113His/His, 4.0{\%} for 139Arg/Arg, and 46.5{\%} for -613C/T. mEH 113His/His homozygotes were overrepresented in advanced stages of disease, in particular among HCC patients (27.9{\%}; P = .03; OR, 2.2; 95{\%} CI, 1.0-4.6). Differences were more pronounced among men and between extreme patient categories. When mEH genotypes were combined to express a metabolic phenotype, very slow metabolizers were highly prevalent among cirrhotic and HCC patients (18{\%} vs. 3.3{\%} in carriers; P <.001). In conclusion, mEH gene polymorphisms were significantly associated with HCV-related liver disease severity and HCC risk. Men were at higher risk than women; this might be explained by hormonal regulation of gene expression or by differential exposure to environmental toxins.",
author = "Laura Sonzogni and Laura Silvestri and {De Silvestri}, Annalisa and Chiara Gritti and Luciana Foti and Claudio Zavaglia and Riccardo Bottelli and Mondelli, {Mario U.} and Emilio Civardi and Silini, {Enrico M.}",
year = "2002",
doi = "10.1053/jhep.2002.33898",
language = "English",
volume = "36",
pages = "195--201",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease

AU - Sonzogni, Laura

AU - Silvestri, Laura

AU - De Silvestri, Annalisa

AU - Gritti, Chiara

AU - Foti, Luciana

AU - Zavaglia, Claudio

AU - Bottelli, Riccardo

AU - Mondelli, Mario U.

AU - Civardi, Emilio

AU - Silini, Enrico M.

PY - 2002

Y1 - 2002

N2 - Factors influencing the progression of liver disease and the development of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV) infection are poorly understood. Inherited variations of drug-metabolizing enzyme (DME) activities may affect liver damage and cancer risk by modifying individual susceptibility to endogenous or exogenous toxic compounds. We investigated the association of liver disease severity with common alleles of microsomal epoxide hydrolase (mEH), an enzyme involved in the metabolism of highly reactive epoxide intermediates. Three polymorphisms (Tyr113His, His139Arg, and -613C/T) were analyzed by polymerase chain reaction (PCR) restriction fragment length polymorphisms (RFLPs) in 394 patients at different stages of disease, including 92 asymptomatic carriers, 109 patients with chronic hepatitis, 100 patients with cirrhosis, and 93 patients with HCC. Reference allele frequencies were obtained from 99 healthy blood donors. Allele distributions between categories were compared using the χ2 test; odds ratios (ORs) and 95% CI were calculated to express relative risks. Allele frequencies among 99 healthy controls were as follows: 15.1% for 113His/His, 4.0% for 139Arg/Arg, and 46.5% for -613C/T. mEH 113His/His homozygotes were overrepresented in advanced stages of disease, in particular among HCC patients (27.9%; P = .03; OR, 2.2; 95% CI, 1.0-4.6). Differences were more pronounced among men and between extreme patient categories. When mEH genotypes were combined to express a metabolic phenotype, very slow metabolizers were highly prevalent among cirrhotic and HCC patients (18% vs. 3.3% in carriers; P <.001). In conclusion, mEH gene polymorphisms were significantly associated with HCV-related liver disease severity and HCC risk. Men were at higher risk than women; this might be explained by hormonal regulation of gene expression or by differential exposure to environmental toxins.

AB - Factors influencing the progression of liver disease and the development of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV) infection are poorly understood. Inherited variations of drug-metabolizing enzyme (DME) activities may affect liver damage and cancer risk by modifying individual susceptibility to endogenous or exogenous toxic compounds. We investigated the association of liver disease severity with common alleles of microsomal epoxide hydrolase (mEH), an enzyme involved in the metabolism of highly reactive epoxide intermediates. Three polymorphisms (Tyr113His, His139Arg, and -613C/T) were analyzed by polymerase chain reaction (PCR) restriction fragment length polymorphisms (RFLPs) in 394 patients at different stages of disease, including 92 asymptomatic carriers, 109 patients with chronic hepatitis, 100 patients with cirrhosis, and 93 patients with HCC. Reference allele frequencies were obtained from 99 healthy blood donors. Allele distributions between categories were compared using the χ2 test; odds ratios (ORs) and 95% CI were calculated to express relative risks. Allele frequencies among 99 healthy controls were as follows: 15.1% for 113His/His, 4.0% for 139Arg/Arg, and 46.5% for -613C/T. mEH 113His/His homozygotes were overrepresented in advanced stages of disease, in particular among HCC patients (27.9%; P = .03; OR, 2.2; 95% CI, 1.0-4.6). Differences were more pronounced among men and between extreme patient categories. When mEH genotypes were combined to express a metabolic phenotype, very slow metabolizers were highly prevalent among cirrhotic and HCC patients (18% vs. 3.3% in carriers; P <.001). In conclusion, mEH gene polymorphisms were significantly associated with HCV-related liver disease severity and HCC risk. Men were at higher risk than women; this might be explained by hormonal regulation of gene expression or by differential exposure to environmental toxins.

UR - http://www.scopus.com/inward/record.url?scp=18444409370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444409370&partnerID=8YFLogxK

U2 - 10.1053/jhep.2002.33898

DO - 10.1053/jhep.2002.33898

M3 - Article

VL - 36

SP - 195

EP - 201

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -